Stockscreener 앱 받기
5.11
0.20%
-0.010
시장 영업 전:
5.04
-0.07
-1.37%
전일 마감가:
$5.12
열려 있는:
$5.12
하루 거래량:
553.10K
Relative Volume:
0.66
시가총액:
$1.15B
수익:
$596.48M
순이익/손실:
$123.72M
주가수익비율:
9.318
EPS:
0.5484
순현금흐름:
$106.59M
1주 성능:
-0.97%
1개월 성능:
-2.29%
6개월 성능:
+19.67%
1년 성능:
+59.19%
1일 변동 폭
$5.0545
$5.135
1주일 범위
$5.0545
$5.31
52주 변동 폭
$2.475
$5.72
큐어백 Stock (CVAC) Company Profile
CVAC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CVAC
Curevac N V
|
5.11 | 1.15B | 596.48M | 123.72M | 106.59M | 0.5484 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
큐어백 Stock (CVAC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-13 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-04-25 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-06-08 | 개시 | SVB Securities | Outperform |
| 2023-01-19 | 업그레이드 | UBS | Neutral → Buy |
| 2023-01-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-01-21 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-01-18 | 개시 | JMP Securities | Mkt Outperform |
| 2021-10-22 | 개시 | Deutsche Bank | Hold |
| 2021-06-17 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-04-26 | 재개 | Credit Suisse | Underperform |
| 2021-04-26 | 개시 | Guggenheim | Neutral |
| 2020-12-10 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2020-09-08 | 개시 | BofA Securities | Buy |
| 2020-09-08 | 개시 | Credit Suisse | Neutral |
| 2020-09-08 | 개시 | Jefferies | Hold |
모두보기
큐어백 주식(CVAC)의 최신 뉴스
Trading Recap: Chien thuat ca cuoc dai han de kiem tienQuarterly Earnings Summary & Daily Growth Stock Tips - BỘ NỘI VỤ
Can CureVac N.V. stock reach $100 price targetWeekly Trade Analysis & Free Risk Controlled Daily Trade Plans - Newser
CureVac N.V. (CVAC): A Bull Case Theory - Finviz
Can CureVac N.V. stock sustain market leadershipGlobal Markets & Proven Capital Preservation Tips - Newser
BioNTech Satisfies Minimum Condition in CureVac Exchange Offer - TipRanks
BioNTech satisfies minimum condition in CureVac exchange offer - MSN
Biontech achieves minimum condition in CureVac exchange offer - marketscreener.com
BioNTech Achieves Minimum Condition in CureVac Exchange Offer - The Manila Times
BioNTech Announces Successful Tender of Over 81% of CureVac Shares, Subsequent Offering Period Now Open - Quiver Quantitative
BioNTech Achieves Minimum Condition in CureVac Exchange Offer - Benzinga
Movement Recap: Can MFSG stock resist broad market declinesQuarterly Performance Summary & Free Low Drawdown Momentum Trade Ideas - BỘ NỘI VỤ
Can New Board Leadership at CureVac (CVAC) Shift the Narrative After Recent Earnings Decline? - simplywall.st
CureVac NV Faces Valuation Shift Amid Declining Financial Performance Indicators - Markets Mojo
How CureVac N.V. stock reacts to Fed rate cutsEarnings Risk Report & Reliable Volume Spike Trade Alerts - BỘ NỘI VỤ
Carlson Capital L.P. Makes New Investment in CureVac N.V. $CVAC - MarketBeat
Transcript : CureVac N.V.Shareholder/Analyst Call - MarketScreener
CureVac (NASDAQ:CVAC) Sees Large Volume IncreaseHere's What Happened - MarketBeat
BioNTech Advances with CureVac Exchange Offer Approval - TipRanks
[6-K] BioNTech SE Current Report (Foreign Issuer) | BNTX SEC FilingForm 6-K - Stock Titan
CureVac Reports Q3 2025 Financial Results and Updates - MSN
CureVac Shareholders Approve BioNTech Exchange Offer - TipRanks
BioNTech’s acquisition of CureVac nears completion as offer deadline approaches - Investing.com Nigeria
CureVac Form 6-K files EGM voting outcomes, joins BioNTech F-4 - Stock Titan
BioNTech (BNTX) Moves Forward with CureVac Acquisition - GuruFocus
BioNTech’s exchange offer for German mRNA vaccine peer CureVac set to expire Dec. 3 - Seeking Alpha
BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration - The Manila Times
BioNTech Completes CureVac Share Exchange Offer Following Shareholder Approval - Quiver Quantitative
BioNTech Says CureVac Shareholders Are Advised To Tender Their Shares By 6:00 P.M. Eastern Time On Tuesday, December 2, 2025 - TradingView
BioNTech exchange offer for CureVac expires December 3 - StreetInsider
CureVac NV earnings beat by €0.08, revenue topped estimates - Investing.com South Africa
CureVac NV (FRA:5CV) PS Ratio : 14.01 (As of Nov. 25, 2025) - GuruFocus
EQS-News: CureVac Announces Voting Results of Extraordinary General Meeting - sharewise.com
CureVac (Nasdaq: CVAC) shareholders approve BioNTech exchange offer with 99.16% vote - Stock Titan
CureVac Announces Voting Results of Extraordinary General Meeting - The Derrick
How Investors May Respond To CureVac (CVAC) Reporting Sharp Decline in Quarterly Sales - Yahoo Finance
CureVac Beats Revenue Forecasts As BioNTech Takeover Advances - Finimize
CureVac (NASDAQ:CVAC) Releases Quarterly Earnings Results, Beats Expectations By $0.07 EPS - MarketBeat
CureVac: Acquisition proceeding as planned; cash runway confirmed through 2028 - marketscreener.com
Company News for Nov 25, 2025 - sharewise.com
CureVac N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
MSN Money - MSN
CureVac Reports Q3 2025 Financials and BioNTech Transaction Progress - TipRanks
CVAC: Q3 2025 profit driven by one-time U.S. settlement, despite sharp revenue drop - TradingView
EQS-News: CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates - sharewise.com
Nasdaq Surges 350 Points; Enlivex Therapeutics Shares Spike Higher - Benzinga
[6-K] CureVac N.V. Current Report (Foreign Issuer) | CVAC SEC FilingForm 6-K - Stock Titan
CureVac BV (CVAC) Reports Q3 Earnings with Strong Cash Position - GuruFocus
CureVac (CVAC) Reports Decrease in Q3 EPS - GuruFocus
CureVac (CVAC) Moves Closer to BioNTech Deal for mRNA Innovations - GuruFocus
큐어백 (CVAC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.45%
0.12%
자본화:
|
볼륨(24시간):